TY -的T1 -等离子体神经胶质原纤维酸性蛋白与先进的疾病和治疗反应的特点在二级进展型多发性硬化症(1782)JF -神经学乔-神经学六世- 94 - 15补充Jens Kuhle SP - 1782 AU - AU - Harald Kropshofer盟Aleksandra Maleska Maceski AU -弗兰克Dahlke盟-托马斯哈希盟Davorka首页 Tomic AU -路德维希卡波斯盟大卫Leppert Y1 - 2020/04/14 UR - //www.ez-admanager.com/content/94/15_Supplement/1782.abstract N2 -目的:评估等离子胶质原纤维酸性蛋白(GFAP)是否有资格作为一个标记的疾病进展和治疗反应活动继发型多发性硬化(spm)患者/没有复发。GFAP的背景:Upregulation astrocyte-specific骨架蛋白,被认为是与疾病相关的活动和进展MS.Design /方法:GFAP水平以一批475名随机挑选的spm患者从第三阶段(siponimod比安慰剂)的扩展研究单分子年底基线(提单)和阵列技术研究(EOS,时间在研究中位数:21个月)。Crossectional GFAP在提单和疾病的关联特征(Mantel-Haenszel趋势/ Jonckheere-Terpstra测试),治疗效果对GFAP水平在EOS (Wilcoxon排名),疾病和病人/参数预测GFAP水平EOS(多元线性回归模型)进行了分析。Results: At BL, older age, longer disease duration (p<0.0001, both), high Expanded Disability Status Scale (EDSS) score (p=0.0003), low Symbol Digit Modalities Test (SDMT) score (p=0.016), number of contrast enhancing lesions (p=0.0137) and volume of T2 lesions (p<0.0001) were associated with higher GFAP levels, while the presence of relapses in the 2 years before BL was not. GFAP levels increased by 7.0% (92.1 vs 98.6 pg/mL) at EOS with placebo but decreased by 1.0% (91.5 vs 90.6 pg/mL) with siponimod treatment (p<0.0001). In the subgroup with relapses before study (n=181), GFAP decreased by 0.5% (92.9 vs 92.4 pg/mL) with siponimod, and increased by 6.3% (98.2 vs 104.4 pg/mL) with placebo (p=0.0296). In the subgroup without relapses before study (n=293), GFAP decreased by 1.5% (90.4 vs 89.1 pg/mL) with siponimod, and increased by 7.3% (89.3 vs 95.8 pg/mL) with placebo (p=0.0004).Conclusions: These results in SPMS support the value of plasma GFAP as a treatment responsive marker of MS pathology related to both inflammatory activity and accumulating disease burden.Disclosure: Dr. Kuhle has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Novartis, Roche, Teva, Merck. Dr. Kuhle has received research support from ECTRIMS Research Fellowship Programme, University of Basel, Swiss MS Society, Swiss National Research Foundation (320030_160221), Bayer, Biogen, Genzyme, Celgene, Novartis, Roche, Teva, Merck.Employee of Novartis.Dr. Maleska Maceski has nothing to disclose. Dr. Dahlke has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Novartis Pharma AG, Basel, Switzerland. Dr. Hach has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Pharma AG.Dr. Tomic has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Novartis.. Dr. Kappos has received research support from Bayer, Biogen, Innosuisse, Novartis, the Swiss MS Society, the Swiss National Research Foundation, and the European Union.Dr. Leppert has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with David Leppert has been Therapeutic Area Head at Novartis, Neuroscience Development Unit, until January 2019. He has received personal compensation for consulting and speaking, and travel reimbursement from Quanterix, Orion and Sanofi.. ER -